Showing 15 posts of 698 posts found.

FDA approves Roche’s Actemra/RoActemra treatment for rare lung disease

March 5, 2021
Medical Communications Actemra, RoActemra, Roche, SEC, systemic sclerosis

Roche’s Actemra/RoActemra therapy, intended for slowing the rate of decline in pulmonary function for adults with systemic sclerosis-associated interstitial lung …


Roche’s influenza drug Xofluza gets EU approval

January 11, 2021
Sales and Marketing EC, Roche, influenza

The European Commission (EC) has approved Roche’s Xofluza (baloxavir marboxil) for the treatment of uncomplicated influenza in patients aged 12 …

Roche secures emergency FDA approval for COVID-19 antibody test

December 3, 2020
Sales and Marketing COVID-19, FDA, Roche

The FDA has awarded Emergency Use Authorization to Roche’s COVID-19 test to allow users in the US to analyse the …


FDA greenlights Gavreto for advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer in over-12s

December 2, 2020
Research and Development, Sales and Marketing FDA, Gavreto, Roche

The FDA has awarded accelerated approval to Roche and Blueprint Medicines’ Gavreto (pralsetinib) for the treatment of advanced or metastatic …

FDA approves Venclexta combo in acute myeloid leukaemia, despite it missing main study goal

October 19, 2020
Sales and Marketing AbbVie, FDA, Roche, Venclexta, pharma

The FDA has given approval to AbbVie and Roche’s jointly-developed BCL-2 inhibitor Venclexta (venetoclax) in combination with azacitidine, decitabine, or low-dose …


Judge allows $1.5 billion Tamiflu stockpiling lawsuit against Roche to go ahead

September 30, 2020
Research and Development Roche, Tamiflu

A Maryland federal judge denied Roche’s motion to throw out a lawsuit that alleges the company defrauded the US and …


Roche says its rheumatoid arthritis drug reduces the need for ventilators in coronavirus patients

September 18, 2020
Medical Communications COVID-19, Roche

Roche says that its Actermra/Roactemra drugs reduce the likelihood that coronavirus patients with virus-related pneumonia will need to be put …


Roche to start new trials of Ocrevus to defend multiple sclerosis franchise

September 9, 2020
Research and Development MS, MS drug, Roche

Roche is to begin expanding trials of Ocrevus in multiple sclerosis (MS) patients to defend its MS franchise from its …


China approves its first biosimilar of Roche’s Herceptin in HER2+ cancers

August 18, 2020
Manufacturing and Production, Sales and Marketing China, Henlius, Herceptin, Roche, biosimilar

China’s National Medical Products Administration (NMPA) has given the green light to Shanghai’s Henlius for its biosimilar version of Roche’s …


Roche’s entrolizumab disappoints at Phase 3 in moderately to severely active ulcerative colitis

August 11, 2020
Manufacturing and Production, Research and Development Roche, etrolizumab, trial failure, ulcerative colitis

Roche has voiced its disappointment after its investigational therapy etrolizumab showed “mixed results” as a treatment for moderately to severely …


Genentech’s Evrysdi becomes first FDA-approved oral treatment for spinal muscular atrophy

August 10, 2020
Sales and Marketing Evrysdi, FDA, Genentech, Roche, spinal muscular atrophy

Genentech’s Evrysdi (risdiplam) has secured FDA approval for the treatment of spinal muscular atrophy (SMA), making it the first oral therapy …


Top Ten most popular articles on this week

July 31, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, Roche, UK government, Vaccine, lilly, pharma, top 10

Another week dominated by COVID-19. Among our most popular stories this week, Celltrion’s infliximab biosimilar Remsima has scored approval for …


UCB syncs up with Roche and Genentech in Alzheimer’s drug deal worth a potential $2bn+

July 30, 2020
Research and Development, Sales and Marketing Genentech, Roche, UCB, partnership

UCB Pharma is set to partner up with Roche and Genentech in a development and commercialisation deal focused on its …


Roche’s Actemra fails to improve clinical status in COVID-19-associated pneumonia

July 29, 2020
Research and Development Actemra, COVID-19, Roche, pharma

Roche has announced the disappointing news that its therapy Actemra/RoActemra (tocilizumab) failed to improve clinical status to a statistically significant …


Roche and Blueprint extend collaboration with $1.7 billion cancer drug development and commercialisation deal

July 14, 2020
Manufacturing and Production, Research and Development Blueprint Medicines, Cancer, Roche, pralsetinib

Roche and Blueprint Medicines have come together in a $1.7 billion development and commercialisation partnership focused on precision therapy pralsetinib …

Latest content